Income statement, balance sheet and cash flow statement for the last 4 fiscal years, taken from the XBRL data Neuphoria Therapeutics Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2024
FY2024
FY2025
FY2026
Revenue
15.6
1.17
Research and development
13.1
9.42
9.01
General and administrative
8.91
8.47
7.77
7.44
Operating expenses
22
17.9
16.8
17.6
Operating income
-22
-17.9
-1.13
-16.5
Interest income
0.32
0.22
0.17
0.67
Other non-operating income
0.46
2.31
0.29
2.86
Pre-tax income
-21.5
-15.6
-0.84
-13.6
Income tax
-0.14
-0.09
-0.47
-0.14
Net income
-21.4
-15.5
-0.37
-13.5
EBITDA
-21.3
-17.2
-0.47
-15.8
EPS, basic
-37.24
-18.62
-0.23
-3.06
EPS, diluted
-37.24
-18.62
-0.23
-3.06
Shares, basic (weighted)
0.79
0.83
1.62
4.4
Shares, diluted (weighted)
0.79
0.83
1.62
4.4
Balance sheet
FY2024
FY2024
FY2025
FY2026
Cash and equivalents
12.1
12.6
14.2
19.9
Receivables
0.43
0.13
0.01
0.81
Other current assets
0.8
0.46
0.74
0.39
Total current assets
13.3
13.2
15
21.1
Property, plant and equipment
0
0
0
Lease right-of-use assets
0.33
0.22
0.1
Goodwill
8.69
8.69
8.64
3.5
Intangible assets
6.13
5.47
4.8
4.14
Total assets
28.6
27.6
28.6
28.7
Accounts payable
1.44
2.24
1.15
0.39
Total current liabilities
2.74
3.83
4.22
0.76
Lease liabilities
0.24
0.12
Other non-current liabilities
0.01
0
Total liabilities
6.55
10.2
9.59
4.11
Paid-in capital
188
198
200
218
Retained earnings
-162
-178
-178
-192
Other comprehensive income
-3.06
-3.01
-2.85
-2.06
Shareholders' equity
22
17.5
19
24.6
Total equity
22
17.5
19
24.6
Total liabilities and equity
28.6
27.6
28.6
28.7
Shares outstanding
0.79
1.1
1.98
5.41
Cash flow statement
FY2024
FY2024
FY2025
FY2026
Net income
-21.4
-15.5
-0.37
-13.5
Depreciation and amortization
0.66
0.66
0.66
0.66
Stock-based compensation
1.35
0.81
0.16
0.35
Deferred income tax
-0.14
-0.14
-0.47
-0.14
Change in receivables
4.14
0.3
0.11
-0.8
Change in payables
0.37
0.8
-0.92
-0.77
Cash from operations
-14.6
-14.7
0.08
-12.4
Stock issued
10.1
1.53
17.9
Cash from financing
3.86
15.1
1.53
17.9
Exchange rate effect
-0.24
0.08
-0
0.01
Net change in cash
-10.8
0.5
1.6
5.58
Interest paid
0.03
0.02
0
Income taxes paid
0.05
Key metrics
Worked out from the statements above. Latest values use fiscal 2026. Valuation uses the share price of $2.71 on November 11, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-1,401.0%
Operating income / revenue.
EBITDA margin
-1,345.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-1,158.0%
Pre-tax income / revenue.
Net margin
-1,146.0%
Net income / revenue.
Operating cash flow margin
-1,052.0%
Cash from operations / revenue.
Return on equity (ROE)
-61.7%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-47.0%
Net income / average total assets.
Return on invested capital (ROIC)
-272.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Stock-based pay / revenue
29.9%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
56.5%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-92.5%
Revenue vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-16,095.0%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
29.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
3.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
0.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
0.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Share count change, 1y
170.9%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
77.3%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
27.8x
Current assets / current liabilities.
Quick ratio
27.3x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
26.3x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
EPS, basic
-$3.06
Net income per basic share, as reported (split-adjusted).
Revenue per share
$0.27
Revenue / diluted weighted shares.
Operating cash flow per share
-$2.81
Cash from operations / diluted weighted shares.
Book value per share
$4.55
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
12.5x
Market cap / revenue.
P/B
0.60x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
0.86x
Market cap / tangible book value, when positive.
Earnings yield
-91.8%
Net income / market cap (the inverse of P/E).
What was Neuphoria Therapeutics Inc.'s revenue in fiscal 2026?
Neuphoria Therapeutics Inc. reported revenue of $1.2M for fiscal 2026, 92.5% lower than the year before.
Was Neuphoria Therapeutics Inc. profitable in fiscal 2026?
No. It reported a net loss of $13.5M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.